论文部分内容阅读
瑞士仿制药商阿特维斯(Actavis)和加拿大制药商Valeant Pharma的2款腹泻型肠易激综合征(IBS-D)新药Viberzi(eluxadoline)和Xifaxan(rifaximin,利福昔明)近日双双获得FDA批准。这2个新产品的上市,将帮助缓解IBS-D患者2种重要的疾病症状(腹泻和腹痛)。Viberzi是一种首创的口服有效、局部作用治疗药物,具有独特的作用机制;该药具有混合的阿片受体活性,是μ受体拮抗剂,也是delta受体激动剂和kappa受体激动剂。在2个III期临床研究中,相比安慰剂Viberzi能够显著减轻IBS-D患者的腹痛及腹泻症状。然而,该药也
Recently both Viberzi (eluxadoline) and Xifaxan (rifaximin), two new antiasthmatic syndromes (IBS-D) from the German generic drug maker Actavis and the Canadian drug maker Valeant Pharma, FDA approval. The two new products will be listed to help alleviate two important symptoms of illness (diarrhea and abdominal pain) in patients with IBS-D. Viberzi is a pioneering orally active, topical therapeutic drug with a unique mechanism of action; it has mixed opioid receptor activity and is a μ receptor antagonist, a delta receptor agonist and a kappa receptor agonist. In two phase III clinical studies, Viberzi significantly reduced abdominal pain and diarrhea in patients with IBS-D compared to placebo. However, the drug also